^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug:FL118 (DDX5 degrader)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASCO 2020
    Title:

    Sensitivity of colorectal or pancreatic cancers with high DDX5 and mutations in Kras and p53 genes to FL118 treatment.

    Published date:
    05/28/2020
    Excerpt:
    PDAC PDX tumors with mp53 exhibit higher mKras expression and greater sensitivity to FL118 than tumors with wild type p53 and mKras….DDX5, mKras and mp53 appears to be favorable biomarkers for predicting FL118 high efficacy.
    DOI:
    10.1200/JCO.2020.38.15_suppl.e16102